Advisory Committee; Peripheral and Central Nervous System Drugs Advisory Committee; Termination and Reestablishment
The Food and Drug Administration (FDA) is announcing the termination and reestablishment of the Peri...
Publisher
USA
This page provides a limited summary and publisher metadata to support discovery before sending readers to the original article.
Read originalAt a glance
- Publisher
- Federal Register
- Region
- USA
- Scope
- Regulatory
- Published
- July 23, 2026
- Language
- EN
In-platform summary, original article off-platform
This page presents the title, publisher metadata, and a limited summary excerpt to help users judge relevance first. Full-text reading stays on the publisher's original site.
Summary excerpt
The Food and Drug Administration (FDA) is announcing the termination and reestablishment of the Peri...
Source route
Continue on federalregister.gov
Leave the platform to read the original full article on the publisher site.
Source: Federal Register
Scope: Regulatory
Related coverage
More related coverage
HeartSine® Samaritan® PAD SAM 350P/SAM 360P/SAM 500P - Membrane Tail
Stryker has recently identified an issue with the membrane tail, an internal component, which could...
The device that raised the alarm and saved my life
Notice of Public Data Asset Release Under the Open, Public, Electronic, and Necessary (OPEN) Government Data Act
In accordance with Title II of the Foundations for Evidence- Based Policymaking Act of 2018, known a...
Availability of Draft Toxicological Profile for Xylene; Extension of Comment Period
On May 5, 2026, the Agency for Toxic Substances and Disease Registry (ATSDR), within the Department...